Fresenius Medical Care offers asymmetric turnaround upside as margin expansion and FME25+ savings confront U.S. volume and reimbursement risks.
Overview
Fresenius Medical Care is the leading vertically integrated renal-care company, combining approximately 3,600 dialysis facilities serving more than 290,000 patients with a global dialysis-equipment franchise. Care Delivery provides recurring, non-discretionary cash flow, while Care Enablement manufactures approximately 47% of dialysis machines and 41% of dialyzers globally; Value-Based Care adds risk-sharing contracts through Interwell Health. **The central investment case is a margin-recovery turnaround rather than a high-growth story.** Q2 2026 revenue rose 1% reported, 4% constant currency, and 5% organically to EUR 4,861 million, while adjusted EBIT rose 20% to EUR 569 million and margin expanded 180 basis points to 11.7%. The key weakness was a 0.9% decline in U.S. same-market treatment volumes. FME25+ targets EUR 1.2 billion of annual sustainable savings by 2027, and 5008X CAREsystem deployment could strengthen clinical differentiation. At $24.27, FMS trades at 12.0x normalized P/E versus DaVita at 14.3x and a sector average of 21.7x. The DCF implies $43.55 intrinsic value, while the probability-weighted five-year target is $60.34. Near-term catalysts are referral recovery, 5008X adoption, and cost savings; principal risks are TDAPA reimbursement roll-off, labor inflation, leverage, and GLP-1-driven volume pressure.